

# MCP-3 (G-2): sc-515890

## BACKGROUND

Eotaxin and the monocyte chemoattractant proteins, MCP-1–5, form a subfamily of the C-C (or  $\beta$ ) chemokines, which are characterized by a set of conserved adjacent cysteines. MCPs are produced by a variety of cells, including T lymphocytes, subsequent to their activation with cytokines such as IL-1, TNF $\alpha$  and IFN- $\gamma$ . *In vitro* studies have shown that the MCP isoforms exhibit their chemotactic effects on different subpopulations of lymphocytes. MCP-3 has been shown to have the broadest range of influence, activating monocytes, dendritic cells, lymphocytes, NK cells, eosinophils, basophils and neutrophils.

## REFERENCES

1. Charo, I.F., et al. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. *Proc. Natl. Acad. Sci. USA* 91: 2752-2756.
2. Taub, D.D., et al. 1995. Monocyte chemoattractant protein-1 (MCP-1), -2 and -3 are chemotactic for human T lymphocytes. *J. Clin. Invest.* 95: 1370-1376.
3. Weber, M., et al. 1995. Monocyte chemoattractant protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3. *J. Immunol.* 154: 4166-4172.
4. Combadiere, C., et al. 1995. Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. *J. Biol. Chem.* 270: 29671-29675.
5. Proost, P., et al. 1996. Human monocyte chemoattractant proteins-2 and -3: structural and functional comparison with MCP-1. *J. Leukoc. Biol.* 59: 67-74.
6. Dubois, P.M., et al. 1996. Early signal transduction by the receptor to the chemokine monocyte chemoattractant protein-1 in a murine T cell hybrid. *J. Immunol.* 156: 1356-1361.
7. Beall, C.J., et al. 1996. Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity. *Biochem. J.* 313: 633-640.
8. Kuna, P., et al. 1996. Chemokines in seasonal allergic rhinitis. *J. Allergy Clin. Immunol.* 97: 104-112.

## CHROMOSOMAL LOCATION

Genetic locus: CCL7 (human) mapping to 17q12.

## SOURCE

MCP-3 (G-2) is a mouse monoclonal antibody raised against amino acids 43-99 mapping at the C-terminus of MCP-3 of human origin.

## PRODUCT

Each vial contains 200  $\mu$ g IgG<sub>1</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## APPLICATIONS

MCP-3 (G-2) is recommended for detection of MCP-3 of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Suitable for use as control antibody for MCP-3 siRNA (h): sc-72035, MCP-3 shRNA Plasmid (h): sc-72035-SH and MCP-3 shRNA (h) Lentiviral Particles: sc-72035-V.

Molecular Weight of MCP-3: 11 kDa.

## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG $\kappa$  BP-HRP: sc-516102 or m-IgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgG $\kappa$  BP-FITC: sc-516140 or m-IgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

## DATA



MCP-3 (G-2): sc-515890. Western blot analysis of human recombinant MCP-3.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.